Area of research
Hematology · Genetics
Research interest
Research focused on PRC2 and EZH2, with related work in Clinical endpoint, Pembrolizumab, AMPK. Notable publications include 'Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer', 'AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells', and 'Mapping Cellular Hierarchy by Single-Cell Analysis of the Cell Surface Repertoire'.
Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA.
Inactivation of Eed impedes MLL-AF9–mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Mapping Cellular Hierarchy by Single-Cell Analysis of the Cell Surface Repertoire
Polycomb repressive complex 2 is required for MLL-AF9 leukemia